Decision Resources, Inc., Nov 2011
-sizing), driven mostly by global economics and payer cost-containment initiatives, but many Big Pharma managements are now also aggressively working to change their company’s behavioral culture and R
Cambridge Healthtech Institute, Aug 2010, Pages: 320
. Goldfarb is Managing Director of First Clinical Research LLC, a provider of clinical research best practices information, consulting and training services. Bio/PharmaR&D Statistical Sourcebook 2010/2011
Takeda Pacific, June 2007, Pages: 130
This report focuses on the market for biomarkers and tests used in pharma/ biotech drug R&D. The study reviews the market by looking at key alliances, pharma/ biotech research and development
Dion Global Solutions Ltd., April 2010, Pages: 15
.4 Effect of Recession on Pharmaceutical R&D
4.5 Outlook 2010-2011 Role of Emerging Markets in PharmaR&D: An Analysis
Datamonitor, July 2010, Pages: 30
In an era of dwindling product pipelines and looming patent expirations, the pain of drug development is particularly acute for pharma. To increase the R&D productivity ratio and reduce the risk
GBI Research, Dec 2011, Pages: 86
released its latest research, “Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma”. It provides
Espicom Business Intelligence Ltd, Nov 2007, Pages: 614
intelligence - has published The PharmaR&D Fact Book 2007.
This essential report examines the research investment and drug pipelines for 39 leading companies from Abbott and Alcon to UCB and Wyeth. A complete
Datamonitor, May 2009, Pages: 79
, despite the costs and risks involved in drug development, the pharma industry is finding new ways to streamline the R&D process in an effort to increase efficiency and output.
- Overview of ongoing trends
Takeda Pacific, July 2005, Pages: 168
in 2004. The study reveals that molecular diagnostic companies are poised for continued strong growth. The mix of pharma/ biotech companies doing biomarker related R&D is also beginning to show gains
GlobalData, Aug 2011, Pages: 7
Increasing Collaboration Between Big Pharma and Academia to Counter R&D, Patent and Approval Issues in the Industry
Summary
GlobalData’s viewpoint, “Increasing Collaboration Between Big Pharma
Bioseeker, Sep 2007, Pages: 500
This is the report for professionals interested to grasp big pharma’s R&D strategy in oncology and at the same time have an extensive R&D overview of the leukemia and lymphoma field. This extensive
John Wiley and Sons Ltd, Nov 2008, Pages: 136
World.
PART 4: THE FUTURE.
Chapter 11: Big Pharma’s Day Has Passed.
Chapter 12: Final Reflections.
References.
Acknowledgements.
Index. Drug Truths: Dispelling the Myths About PharmaR & D
Biopharm Knowledge Publishing, June 2008, Pages: 108
Diversity
2.5 A Question of Scale
2.6 A Question of Focus
2.7 A Question of Efficiency
2.8 Big & Middle Pharma Tables Ranked by 2007 Sales Revenues
2.8.1 2000-2006 Mid Pharma SG&A
2.8.2 2000-2006 Mid PharmaR
Decision Resources, Inc., May 2007, Pages: 27
Stakeholder Implications
An Aspirational Business Model
Transformational Drivers
Paucity of New Products
Parsimony of Customers
Pharma’s Aversion to Risk
R&D Polarization
Lure and Trap of Patents
JZMed Inc., Oct 2011, Pages: 215
from the innovative small molecule drugs, almost all pharma companies are now putting increasing effort on the development of innovative biologic products, including raising R&D investment in this area
Decision Resources, Inc., Sep 2009, Pages: 24
to change R&D?
- What structures and strategies have already been implemented within Big PharmaR&D organizations?
- Can pharmaceutical companies replicate the innovation of biotech companies by reforming R
MCD Group LLC, Jan 2011, Pages: 203
approved and soon-to-be launched specialty pharma products as well as partnerships and acquisitions. The bulk of the report is in table format for ease of use.
Specialty pharmaceuticals are mainly
MP Advisors, Jan 2012, Pages: 130
stage R&D activities into mainstream products and company's strategic approach- historical and visionary, by giving a premium to their future cumulative R&D investment (Part C). Global Biopharma Outlook
JZMed Inc., April 2010, Pages: 208
changes will ultimately lead to evolving of new operation models across the entire value chain of drug R&D, manufacturing and marketing. As a result, all world major pharma companies will become much
